Sudip Bandopadhyay, Market Expert suggests buying Lupin.
"Some of these companies even at current valuation are definitely good pick. Lupin is a fantastic buy at current levels. There are other good companies in the midcap space as well. As a theme we will once again go back to pharma for 2017. Other than that non banking finance companies (NBFCs) can be the second pick."
"Demonetisation is definitely going to help NBFCs eventually. In the short term there can be some destabilisation, but eventually NBFCs are going to fair well. The entire unorganised market moving to the organised sector will definitely favour the established players, so Capital First, Bajaj Finance almost all the leading NBFCs will benefit," he added.